New Two-Drug pill combo targets tough gynecologic cancers
NCT ID NCT05512208
Summary
This study is testing whether taking two oral drugs, VS-6766 and defactinib, together can help control recurrent gynecologic cancers like ovarian and cervical cancer. It is for women whose cancer has a specific genetic change and has come back or worsened after at least one prior treatment. The main goal is to see if the drug combination shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth
RECRUITINGOrlando, Florida, 32804, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Louisiana State University Medical Center New Orleans
RECRUITINGNew Orleans, Louisiana, 70112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73117, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of New Mexico Comprehensive Cancer Center
RECRUITINGAlbuquerque, New Mexico, 87131, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.